IDH1 and central nervous system cancer: The glioma trial is an open-label, non-randomised, multicentre phase I study to determine the maximum tolerated or recommended phase II dose of oral mutant IDH1 inhibitor BAY1436032 and to characterise its safety, tolerability, pharmacokinetics and preliminary pharmacodynamic and anti-tumour activity in patients with IDH1R132X mutant advanced solid tumours, including gliomas [181] (Table 1).